Decibel Therapeutics Inc.

9.70-0.1400-1.42%Vol 76.21K1Y Perf -45.90%
Apr 20th, 2021 16:00 DELAYED
BID9.70 ASK9.72
Open10.01 Previous Close9.84
Pre-Market- After-Market-
 - -  - -%
Target Price
28.75 
Analyst Rating
— — 0.00
Potential %
196.39 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap241.55M 
Earnings Rating
Price Range Ratio 52W %
2.78 
Earnings Date
-

Today's Price Range

9.3510.01

52W Range

9.2824.39

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-10.43%
1 Month
-34.50%
3 Months
-
6 Months
-
1 Year
-45.90%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
DBTX9.70-0.1400-1.42
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume76.21K
Shares Outstanding24.90M
Trades Count653
Dollar Volume3.28M
Avg. Volume171.97K
Avg. Weekly Volume63.44K
Avg. Monthly Volume100.30K
Avg. Quarterly Volume171.97K

Decibel Therapeutics Inc. (NASDAQ: DBTX) stock closed at 9.7 per share at the end of the most recent trading day (a -1.42% change compared to the prior day closing price) with a volume of 76.21K shares and market capitalization of 241.55M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 37 people. Decibel Therapeutics Inc. CEO is Laurence E. Reid.

The one-year performance of Decibel Therapeutics Inc. stock is -45.9%, while year-to-date (YTD) performance is %. DBTX stock has a five-year performance of %. Its 52-week range is between 9.28 and 24.39, which gives DBTX stock a 52-week price range ratio of 2.78%

Decibel Therapeutics Inc. currently has a PE ratio of -6.50, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of 12.85%, a ROC of -% and a ROE of -8.01%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Decibel Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Decibel Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Decibel Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Decibel Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Decibel Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Decibel Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 53.35, ATR14 : 0.64, CCI20 : -110.82, Chaikin Money Flow : -0.31, MACD : -1.02, Money Flow Index : 37.17, ROC : -13.38, RSI : 27.74, STOCH (14,3) : 23.33, STOCH RSI : 0.00, UO : 41.13, Williams %R : -76.67), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Decibel Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Decibel Therapeutics Inc.

Decibel Therapeutics Inc is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders. It aims to restore and improve hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear.

CEO: Laurence E. Reid

Telephone: +1 617 370-8701

Address: 1325 Boylston Street, Boston 02215, MA, US

Number of employees: 37

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

25%75%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits